financing

Prenetics, which operates in 10 countries, will use the funding for R&D and plans to launch a rapid coronavirus nucleic acid test in Q4.

The company said it will use the capital to accelerate the growth and development of its infrastructure and CRISPR-based chips.

The new company will use Seer's Proteograph proteomic platform along with other omics data to develop and commercialize tests for cancer and other diseases.

The funding will allow the company to accelerate development of its DNA synthesis technology, hire staff, build an R&D facility, and establish industrial partnerships.

The firm will use the funds to build inventory to meet anticipated demand, expand its sales and marketing efforts, and for general corporate purposes.

he single-cell microbiome sequencing firm has raised a total of ¥1.5 billion in equity financing since its founding in 2018.

The Redwood City, California-based company said it will use the funds to add new capabilities to its platforms for producing CRISPR reagents and engineered cells.

The company said proceeds will accelerate the ongoing FDA registrational study of its blood-based colorectal cancer screening test and further its extended pipeline.

The firm said it plans to use the proceeds to support the launch of its first product based on its structures for lossless ion manipulation ion mobility system.